Creaven Pj
About
In The Last Decade
Creaven Pj
19 papers receiving 528 citations
Peers
Comparison fields: 5 of 67
- Oncology 245
- Hematology 230
- Molecular Biology 200
- Public Health, Environmental and Occupational Health 162
- Pathology and Forensic Medicine 92
Countries citing papers authored by Creaven Pj
This map shows the geographic impact of Creaven Pj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Creaven Pj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Creaven Pj more than expected).
Fields of papers citing papers by Creaven Pj
This network shows the impact of papers produced by Creaven Pj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Creaven Pj. The network helps show where Creaven Pj may publish in the future.
Co-authorship network of co-authors of Creaven Pj
This figure shows the co-authorship network connecting the top 25 collaborators of Creaven Pj. A scholar is included among the top collaborators of Creaven Pj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Creaven Pj. Creaven Pj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Metastatic colorectal cancer: advances in biochemical modulation and new drug development. | 20 |
| 2 | 2 | |
| 3 | Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. | 43 |
| 4 | 3 | |
| 5 | Clinical pharmacokinetics of a new antiandrogen Anandron (RU 23908). | 5 |
| 6 | Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP). | 52 |
| 7 | Dialogue en enfer | 4 |
| 8 | Studies on the pharmacokinetics and metabolism of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) in the dog. | 13 |
| 9 | Pharmacokinetic parameters: potential for and problems with their use as predictors of response to cancer chemotherapeutic agents. | 3 |
| 10 | 88 | |
| 11 | 120 | |
| 12 | The clinical toxicity of anticancer drugs and its prediction. | 25 |
| 13 | Studies on the human pharmacokinetics of isophosphamide (NSC-109724). | 49 |
| 14 | Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. | 41 |
| 15 | Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213). | 22 |
| 16 | Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943). | 7 |
| 17 | Renal clearance of camptothecin (NSC-100880): effect of urine volume. | 11 |
| 18 | Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. | 63 |
| 19 | Gas chromatographic method for the determination of plasma isophosphamide (NSC-109724). | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.